Mark A. Meltz's most recent trade in Lyell Immunopharma Inc was a trade of 50,000 Option (right to buy) done . Disclosure was reported to the exchange on Feb. 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Mark A. Meltz | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2026 | 50,000 | 50,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Mark A. Meltz | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 100,000 | 100,000 | - | - | Option (right to buy) | |
| Kinnate Biopharma Inc | Mark A. Meltz | COO GENERAL COUNSEL SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.59 per share. | 01 Mar 2024 | 558 | 27,578 | - | 2.6 | 1,445 | Common Stock |
| Kinnate Biopharma Inc | Meltz A. Mark | COO General Counsel Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.25 per share. | 01 Dec 2023 | 541 | 28,136 | - | 2.2 | 1,217 | Common Stock |
| Kinnate Biopharma Inc | Mark A. Meltz | COO General Counsel Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.30 per share. | 01 Jun 2023 | 541 | 29,218 | - | 4.3 | 2,326 | Common Stock |
| Kinnate Biopharma Inc | Mark A. Meltz | COO General Counsel Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.21 per share. | 01 Mar 2023 | 638 | 27,286 | - | 5.2 | 3,324 | Common Stock |
| Kinnate Biopharma Inc | Mark A. Meltz | COO General Counsel Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 215,000 | 215,000 | - | - | Employee Stock Option (right to buy) | |
| Kinnate Biopharma Inc | Mark A. Meltz | COO General Counsel Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.75 per share. | 01 Dec 2022 | 541 | 27,924 | - | 7.8 | 4,193 | Common Stock |
| Kinnate Biopharma Inc | Mark A. Meltz | COO General Counsel Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 25,000 | 28,465 | - | 0 | Common Stock | |
| Kinnate Biopharma Inc | Mark A. Meltz | COO General Counsel Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) |